TauRx’s LMTX Alzheimer’s drug fails to meet co-primary endpoints in phase 3 trial
The company said treatment with its tau aggregation inhibitor had a marked beneficial effect on key measures of Alzheimer's disease in patients with mild or moderate forms of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.